The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vacci...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-08-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-021-00530-3 |
id |
doaj-4a8f04b6d30e4665bb7e2a6d5fd696c0 |
---|---|
record_format |
Article |
spelling |
doaj-4a8f04b6d30e4665bb7e2a6d5fd696c02021-08-08T11:44:06ZengNature Publishing GroupBlood Cancer Journal2044-53852021-08-011181910.1038/s41408-021-00530-3The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatmentEvangelos Terpos0Maria Gavriatopoulou1Ioannis Ntanasis-Stathopoulos2Alexandros Briasoulis3Sentiljana Gumeni4Panagiotis Malandrakis5Despina Fotiou6Eleni-Dimitra Papanagnou7Magdalini Migkou8Foteini Theodorakakou9Maria Roussou10Evangelos Eleutherakis-Papaiakovou11Nikolaos Kanellias12Ioannis P. Trougakos13Efstathios Kastritis14Meletios A. Dimopoulos15Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of AthensAbstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and MGUS (n = 25) and 226 healthy controls were enrolled in the study (NCT04743388). Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Furthermore, MM patients showed an inferior NAb response compared with MGUS on day 22 (p = 0.009) and on day 50 (p = 0.003). Importantly, active treatment with either anti-CD38 monoclonal antibodies (Mabs) or belantamab mafodotin and lymphopenia at the time of vaccination were independent prognostic factors for suboptimal antibody response following vaccination. In conclusion, MM patients have low humoral response following SARS-CoV-2 vaccination, especially under treatment with anti-CD38 or belamaf. This underlines the need for timely vaccination, possibly during a treatment-free period, and for continuous vigilance on infection control measures in non-responders.https://doi.org/10.1038/s41408-021-00530-3 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Alexandros Briasoulis Sentiljana Gumeni Panagiotis Malandrakis Despina Fotiou Eleni-Dimitra Papanagnou Magdalini Migkou Foteini Theodorakakou Maria Roussou Evangelos Eleutherakis-Papaiakovou Nikolaos Kanellias Ioannis P. Trougakos Efstathios Kastritis Meletios A. Dimopoulos |
spellingShingle |
Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Alexandros Briasoulis Sentiljana Gumeni Panagiotis Malandrakis Despina Fotiou Eleni-Dimitra Papanagnou Magdalini Migkou Foteini Theodorakakou Maria Roussou Evangelos Eleutherakis-Papaiakovou Nikolaos Kanellias Ioannis P. Trougakos Efstathios Kastritis Meletios A. Dimopoulos The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment Blood Cancer Journal |
author_facet |
Evangelos Terpos Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Alexandros Briasoulis Sentiljana Gumeni Panagiotis Malandrakis Despina Fotiou Eleni-Dimitra Papanagnou Magdalini Migkou Foteini Theodorakakou Maria Roussou Evangelos Eleutherakis-Papaiakovou Nikolaos Kanellias Ioannis P. Trougakos Efstathios Kastritis Meletios A. Dimopoulos |
author_sort |
Evangelos Terpos |
title |
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment |
title_short |
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment |
title_full |
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment |
title_fullStr |
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment |
title_full_unstemmed |
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment |
title_sort |
neutralizing antibody response post covid-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment |
publisher |
Nature Publishing Group |
series |
Blood Cancer Journal |
issn |
2044-5385 |
publishDate |
2021-08-01 |
description |
Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and MGUS (n = 25) and 226 healthy controls were enrolled in the study (NCT04743388). Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Furthermore, MM patients showed an inferior NAb response compared with MGUS on day 22 (p = 0.009) and on day 50 (p = 0.003). Importantly, active treatment with either anti-CD38 monoclonal antibodies (Mabs) or belantamab mafodotin and lymphopenia at the time of vaccination were independent prognostic factors for suboptimal antibody response following vaccination. In conclusion, MM patients have low humoral response following SARS-CoV-2 vaccination, especially under treatment with anti-CD38 or belamaf. This underlines the need for timely vaccination, possibly during a treatment-free period, and for continuous vigilance on infection control measures in non-responders. |
url |
https://doi.org/10.1038/s41408-021-00530-3 |
work_keys_str_mv |
AT evangelosterpos theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT mariagavriatopoulou theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT ioannisntanasisstathopoulos theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT alexandrosbriasoulis theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT sentiljanagumeni theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT panagiotismalandrakis theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT despinafotiou theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT elenidimitrapapanagnou theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT magdalinimigkou theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT foteinitheodorakakou theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT mariaroussou theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT evangeloseleutherakispapaiakovou theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT nikolaoskanellias theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT ioannisptrougakos theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT efstathioskastritis theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT meletiosadimopoulos theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT evangelosterpos neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT mariagavriatopoulou neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT ioannisntanasisstathopoulos neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT alexandrosbriasoulis neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT sentiljanagumeni neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT panagiotismalandrakis neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT despinafotiou neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT elenidimitrapapanagnou neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT magdalinimigkou neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT foteinitheodorakakou neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT mariaroussou neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT evangeloseleutherakispapaiakovou neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT nikolaoskanellias neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT ioannisptrougakos neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT efstathioskastritis neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment AT meletiosadimopoulos neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment |
_version_ |
1721215621284233216 |